Brief: Acurx Announces Positive Extended Clinical Cure Data for Ibezapolstat from Phase 2b Clinical Trial In CDI Patients
Brief: Acurx Announces Positive Comparative Microbiology And Microbiome Data For Ibezapolstat From Phase 2b Clinical Trial In CDI Patients
Brief: Acurx Announces Positive Phase 2B Results Showing 100% Of Patients Who Had Clinical Cure With Ibezapolstat Also Had Sustained Clinical Cure
Brief: Acurx Pharmaceuticals Says May Offer & Sell, From Time To Time, Shares Of Common Stock, Par Value $0.001 Per Share Of Up To $17 Mln
Brief: Acurx Pharmaceuticals Q3 EPS USD -0.24
Brief: Acurx Announces Positive Top-Line Ibezapolstat Phase 2 Efficacy Results
U.S. STOCKS ON THE MOVE-American Airlines, Netflix, Tesla
U.S. STOCKS ON THE MOVE-Amazon.com, US airlines, SolarEdge, Dynatronics
U.S. STOCKS ON THE MOVE-Invitae Corp, Aemetis, Discover Financial Services, Nvidia
U.S. STOCKS ON THE MOVE-Guardforce AI, Sphere Entertainment, Acurx Pharma
Acurx Pharma gains after ending colon drug mid-stage trial early
Acurx Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Acurx Pharmaceuticals Inc expected to post a loss of 27 cents a share - Earnings Preview
Brief: Acurx Pharmaceuticals, Inc. Announces Pricing Of $4.0 Million Registered Direct Offering
Brief: Acurx Pharmaceuticals Inc Reports Q1 2023 Results And Provides Business Update
Acurx Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Acurx Pharmaceuticals Inc expected to post a loss of 29 cents a share - Earnings Preview
Brief: FDA Accepts Interim Analysis Plan For Ongoing Phase 2b Ibezapolstat Clinical Trial
Acurx Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary